Tyra Biosciences, Inc. Debt Securities, Available-for-sale
Tyra Biosciences, Inc. (TYRA) had Debt Securities, Available-for-sale of $280.11 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale $280.11M.
- 2026-03-31: Debt Securities, Available-for-sale $298.51M.
- 2025-12-31: Debt Securities, Available-for-sale $178.62M.
- 2025-09-30: Debt Securities, Available-for-sale $212.97M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $280.11M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $298.51M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $178.62M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $212.97M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $197.78M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $218.22M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $249.47M 10-K · filed 2026-03-02 |
| 2024-09-30 | $256.24M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $274.31M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $128.10M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $145.46M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |